Immunosuppressive effect of bredinin in the management of patients with renal transplantation.
Clinical effects of bredinin were evaluated in 18 renal transplant patients. Of 12 cases in which administration of azathioprine was suspended due to liver dysfunction and leucopenia, treatment with bredinin resulted in amelioration of these symptoms without harm to the transplanted kidneys in 10 cases. In six other cases, bredinin was used from the time of renal transplantation, and the postoperative course in four of these cases was uneventful, enabling these patients to return to society. The remaining two patients have had to undergo haemodialysis again as their transplanted kidneys failed to function and they showed severe stomatitis in the early postoperative period. The results of clinical use of bredinin in renal transplant patients suggest that this drug is an effective immunosuppressive agent which is without the drawbacks seen with azathioprine. Nonetheless, one must bear in mind that the function of the transplanted kidney should be evaluated carefully before using this drug.
D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D005260:Female; D006084:Graft Rejection; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D012263:Ribonucleosides / Q000009:adverse effects / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D001379:Azathioprine